Albumin, Dialysis, Redox State, Uremic; Toxemia
Conditions
Brief summary
Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin. The aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties. Our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins. Previous results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.
Interventions
OTHERHemodialysis mode, dialyzer type
Change of hemodialysis mode and dialyzer type
Sponsors
Universität Duisburg-Essen
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen
Exclusion criteria
* Age ≤ 18 years * Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week * Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria) * Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion * Acute or severe chronic infections * Acute tumor disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of irreversibly oxidized albumin HNA-2 | after 9 month | change of human mercaptalbumin-2 HNA-2 |
| Level of albumin binding and detoxification efficiency | after 9 month | Change of albumin binding and detoxification efficiency, meausurement according to PMID: 37558390 |
Countries
Germany
Contacts
Primary ContactKristina Boss, PD
Outcome results
None listed